Related Announcements

RFA-CA-21-060 – NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the language on the Number of Applications in Section III.3, Additional Information on Eligibility of the Funding Opportunity Announcement (FOA) RFA-CA-21-060, "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)".

The following language in the Number of Applications in Section III.3, Additional Information on Eligibility has been modified:

Currently Reads:

Section III. Eligibility Information

3. Additional Information on Eligibility

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. An individual may not have two or more competing NIH career development applications pending review concurrently. In addition, NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Each eligible institution (defined as having a unique DUNS number or NIH IPF number) may submit up to a combined total of three applications to any companion RFA or any combination of companion RFAs (RFA-CA-21-060, RFA-CA-21-061, and/or RFA-CA-21-062).

Modified to Read (changes shown in bold italics):

Section III. Eligibility Information

3. Additional Information on Eligibility

Number of Applications

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. An individual may not have two or more competing NIH career development applications pending review concurrently. In addition, NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Each eligible institution (defined as having a unique DUNS number or NIH IPF number) may submit up to a combined total of three applications (one in Data Science, one in Cancer Control Science, and one in Other Sciences) to any companion RFA or any combination of companion RFAs (RFA-CA-21-060, RFA-CA-21-061, and/or RFA-CA-21-062).

NOTE: All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Sergey Radaev, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5630
Email: [email protected]